These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4327165)

  • 21. Production and characterization of Clostridium perfringens recombinant β toxoid.
    Milach A; de los Santos JR; Turnes CG; Moreira AN; de Assis RA; Salvarani FM; Lobato FC; Conceição FR
    Anaerobe; 2012 Jun; 18(3):363-5. PubMed ID: 22306065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunogenicity and thymus-dependence of the polymerized alpha-toxoid of Clostridium perfringens].
    Petrov RV; Shemanova GF; Kaverzneva ED; Kissel' VL; Panteleev EI
    Biull Eksp Biol Med; 1977 Dec; 84(12):695-8. PubMed ID: 202354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigenic properties of the bacteriocine preparations obtained from type A Cl. perfringens strains.
    Tubylewicz H
    Bull Acad Pol Sci Biol; 1970; 18(5):253-6. PubMed ID: 4322857
    [No Abstract]   [Full Text] [Related]  

  • 24. Biological activities contaminating preparations of phospholipase C ( -toxin) from Clostridium perfringens.
    Möllby R; Nord CE; Wadström T
    Toxicon; 1973 Feb; 11(2):139-47. PubMed ID: 4351816
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunochemical investigations on the antigenic structure of heat resistant "Cl. perfringens" type A strains.
    Meisel-Mikolajczyk F; Dworczyński A; Kubica J
    Prog Immunobiol Stand; 1970; 4():601-8. PubMed ID: 4320521
    [No Abstract]   [Full Text] [Related]  

  • 26. [Purification and some properties of Cl. perfringens lecithinase].
    Ispolatovskaia MV
    Vopr Med Khim; 1971; 17(2):137-41. PubMed ID: 4325641
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pathomorphologic changes in animals with experimental gas infection immunized with Cl. perfringens and oedematiens toxoids].
    Pushkarev AA; Sunargulov TS; Mel'nikov VN
    Zh Mikrobiol Epidemiol Immunobiol; 1974 Jan; (1):132-3. PubMed ID: 4375917
    [No Abstract]   [Full Text] [Related]  

  • 28. [Preparation and evaluation of immunogenic properties of Clostridium perfringens type A toxoid].
    Rymkiewicz D; Sawicki J; Brühl A; Sochańska R
    Med Dosw Mikrobiol; 1979; 31(2):95-102. PubMed ID: 228130
    [No Abstract]   [Full Text] [Related]  

  • 29. Induction of potential protective immunity against enterotoxemia in calves by single or multiple recombinant Clostridium perfringens toxoids.
    Jiang Z; De Y; Chang J; Wang F; Yu L
    Microbiol Immunol; 2014 Nov; 58(11):621-7. PubMed ID: 25197030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of Cl. perfringens collagenase on some synthetic substrates].
    Orekhovich VN; Levdikova GA; Shibnev VA
    Biokhimiia; 1970; 35(3):549-51. PubMed ID: 4319426
    [No Abstract]   [Full Text] [Related]  

  • 31. The antigenic component common to all Clostridium perfringens type A strains.
    Dworczyński A; Meisel-Mikolajczyk F; Kubica J
    Bull Acad Pol Sci Biol; 1969; 17(6):377-80. PubMed ID: 4314805
    [No Abstract]   [Full Text] [Related]  

  • 32. The prevention of experimental Clostridium novyi and Cl. perfringens gas gangrene in high-velocity missile wounds by active immunisation.
    Boyd NA; Thomson RO; Walker PD
    J Med Microbiol; 1972 Nov; 5(4):467-72. PubMed ID: 4345766
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of humoral neutralizing antibody response in rabbits, guinea pigs, and cattle vaccinated with epsilon and beta toxoids from Clostridium perfringens and C. botulinum types C and D toxoids.
    Silva ROS; Duarte MC; Oliveira Junior CA; de Assis RA; Lana AMQ; Lobato FCF
    Anaerobe; 2018 Dec; 54():19-22. PubMed ID: 30076896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows.
    Zeng J; Deng G; Wang J; Zhou J; Liu X; Xie Q; Wang Y
    Vaccine; 2011 Jul; 29(33):5459-66. PubMed ID: 21641956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study on the immunogenic properties of Clostridium perfringens type A toxoid.
    Shemanova GF; Vlasova EV; Dmitrieva LN; Trapezov EV; Gorbacheva LD
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(3):323-9. PubMed ID: 2877025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin E-enhanced humoral antibody response to Clostridium perfringens type D in sheep.
    Tengerdy RP; Meyer DL; Lauerman LH; Lueker DC; Nockels CF
    Br Vet J; 1983; 139(2):147-52. PubMed ID: 6301619
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis.
    Kasper DL; Winkelhake JL; Zollinger WD; Brandt BL; Artenstein MS
    J Immunol; 1973 Jan; 110(1):262-8. PubMed ID: 4346607
    [No Abstract]   [Full Text] [Related]  

  • 38. [Tubule agglutination and indirect immunofluorescence for titer determination during immunization of rabbits with Clostridium (Cl.) perfringens (welchii) type A,C and E].
    Mechler U
    Berl Munch Tierarztl Wochenschr; 1974 Mar; 87(5):93-6. PubMed ID: 4361342
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunopurification of phospholipase C (alpha-toxin) from Clostridium perfringens.
    Bird RA; Low MG; Stephen J
    FEBS Lett; 1974 Aug; 44(3):279-81. PubMed ID: 4370089
    [No Abstract]   [Full Text] [Related]  

  • 40. Large-scale production of clostridial collagenase and lecithinase C: short communication.
    Lettl A
    J Hyg Epidemiol Microbiol Immunol; 1973 Mar; 17(3):385-8. PubMed ID: 4355336
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.